These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340 [TBL] [Abstract][Full Text] [Related]
5. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603 [TBL] [Abstract][Full Text] [Related]
6. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J; Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844 [TBL] [Abstract][Full Text] [Related]
8. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686 [TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. Darwish M; Hellriegel ET Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239 [TBL] [Abstract][Full Text] [Related]
10. Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. Atasayar G; Eryilmaz IE; Karli N; Egeli U; Zarifoglu M; Cecener G; Taskapilioglu O; Tunca B; Yildirim O; Ak S; Tezcan G; Can FE J Neurol Sci; 2016 Jul; 366():149-154. PubMed ID: 27288795 [TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076 [TBL] [Abstract][Full Text] [Related]
13. A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Gutman D; Hellriegel E; Aycardi E; Bigal ME; Kunta J; Chitra R; Kansagra S; Kidron OS; Knebel H; Linder S; Ma Y; Pierce M; Winner PK; Spiegelstein O Headache; 2016 Sep; 56(8):1300-9. PubMed ID: 27474357 [TBL] [Abstract][Full Text] [Related]
14. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Gerber WD; Diener HC; Scholz E; Niederberger U Cephalalgia; 1991 Feb; 11(1):37-45. PubMed ID: 2036669 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic drugs and cytokine and leptin levels in children with migraine. Hirfanoglu T; Serdaroglu A; Gulbahar O; Cansu A Pediatr Neurol; 2009 Oct; 41(4):281-7. PubMed ID: 19748048 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interactions between topiramate and pioglitazone and metformin. Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351 [TBL] [Abstract][Full Text] [Related]
18. A Comparison of Differences Between the Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion: A Prospective, Randomized, Multicenter, Double-Blind Controlled Trial. Perotti L; Cusato M; Ingelmo P; Niebel TL; Somaini M; Riva F; Tinelli C; De Andrés J; Fanelli G; Braschi A; Regazzi M; Allegri M Anesth Analg; 2015 Aug; 121(2):348-56. PubMed ID: 25977992 [TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Jenner P; Könen-Bergmann M; Schepers C; Haertter S Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]